Does Rallies show AQST price targets?

Yes. Rallies tracks AQST analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.

Is AQST research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AQST. It does not provide personalized investment advice.

AQST (Aquestive Therapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings

Aquestive Therapeutics, Inc. Common Stock (AQST) is a publicly traded Healthcare sector company. As of May 21, 2026, AQST trades at $4.15 with a market cap of $518.74M and a P/E ratio of -6.70. AQST moved +2.20% today. Year to date, AQST is -33.07%; over the trailing twelve months it is +74.48%. Its 52-week range spans $2.12 to $7.55. Analyst consensus is strong buy with an average price target of $8.75. Rallies surfaces AQST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate AQST?

8 analysts cover AQST: 0 strong buy, 8 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $8.75.

AQST Key Metrics

Key financial metrics for AQST
Metric	Value
Price	$4.15
Market Cap	$518.74M
P/E Ratio	-6.70
EPS	$-0.62
Dividend Yield	0.00%
52-Week High	$7.55
52-Week Low	$2.12
Volume	4
Avg Volume	0
Revenue (TTM)	$50.27M
Net Income	$-68.91M
Gross Margin	63.45%

AQST Analyst Consensus

8 analysts cover AQST: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.75.

Latest AQST News

Aquestive Therapeutics Q1 Revenues Up 66%, Net Loss Narrows to $8.1M — May 14, 2026
Aquestive Therapeutics narrows Q1 loss, secures $150M debt facility — May 13, 2026
Aquestive Names Thomas Zalewski Chief Legal and Compliance Officer, Grants 100K RSUs and 75K Options — Mar 20, 2026
Cantor Cuts Aquestive Price Target 47% to $8, Triggering 37% Share Plunge — Mar 12, 2026
Aquestive Therapeutics Posts 10% Q4 Revenue Gain, Secures RTW Funding for Anaphylm — Mar 5, 2026

Recent AQST Insider Trades

Barber Daniel sold 8.26K (~$35.41K) on May 15, 2026.
Boyd Peter E. sold 29.81K (~$124.41K) on Mar 10, 2026.
Barber Daniel sold 180.68K (~$753.97K) on Mar 10, 2026.

Common questions about AQST

What do analysts rate AQST?: 8 analysts cover AQST: 0 strong buy, 8 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $8.75.
Does Rallies show AQST price targets?: Yes. Rallies tracks AQST analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is AQST research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AQST. It does not provide personalized investment advice.